Mammographic density and breast cancer risk: the role of the fat surrounding the fibroglandular tissue by Lokate, Mariëtte et al.
RESEARCH ARTICLE Open Access
Mammographic density and breast cancer risk: the
role of the fat surrounding the fibroglandular tissue
Mariëtte Lokate
1, Petra HM Peeters
1,4, Linda M Peelen
1, Gerco Haars
2, Wouter B Veldhuis
3 and Carla H van Gils
1*
Abstract
Introduction: Both the percent of mammographic density and absolute dense (fibroglandular) area are strong
breast cancer risk factors. The role of non-dense (fat) breast tissue is not often investigated, but we hypothesize
that this also influences risk. In this study we investigated the independent effects of dense and fat tissue, as well
as their combined effect on postmenopausal breast cancer risk.
Methods: We performed a nested case-control study within the EPIC-NL cohort (358 postmenopausal breast
cancer cases and 859 postmenopausal controls). We used multivariate logistic regression analyses to estimate
breast cancer odds ratios adjusted for body mass index and other breast cancer risk factors.
Results: Large areas of dense (upper (Q5) vs lower quintile (Q1): OR 2.8 95% CI 1.7 to 4.8) and fat tissue (Q5 vs Q1:
OR 2.4; 95% CI 1.3 to 4.2) were independently associated with higher breast cancer risk. The combined measure
showed that the highest risk was found in women with both a large (above median) area of dense and fat tissue.
Conclusions: Fibroglandular and breast fat tissue have independent effects on breast cancer risk. The results
indicate that the non-dense tissue, which represents the local breast fat, increases risk, even independent of body
mass index (BMI). When studying dense breast tissue in relation to breast cancer risk, adjustment for non-dense
tissue seems to change risk estimates to a larger extent than adjustment for BMI. This indicates that adjustment for
non-dense tissue should be considered when studying associations between dense areas and breast cancer risk.
Introduction
In the last two decades, many researchers have observed
a strongly elevated breast cancer risk in women with a
high percent mammographic density [1,2]. Percent mam-
mographic density represents the relative amount of
fibroglandular tissue, which is radiographically dense,
and fat tissue, which is radiographically lucent. A high
percent mammographic density is associated with a
three-to-six-fold increase in breast cancer risk comparing
the extremes of the breast density distribution [2].
Increasingly, the absolute area of dense tissue is reported
in the literature along with the percent density measure.
The reason for this is that the dense area is considered to
represent the actual target tissue for tumor development
[3,4]. As percent density is strongly influenced by the size
of the fat area, or non-dense tissue, in the breast using a
percentage seems less appropriate. Several studies show
approximately equal results for percent density and abso-
lute dense area [1,5-7], although some others show stron-
ger [8] or weaker results for the absolute dense area [9-11].
Until now, there has been little attention given to the
role of non-dense breast tissue, despite the fact that fat
cells are known to be highly active endocrine cells that
secrete numerous hormones which are thought to be
important for the development of breast cancer [12,13].
The interaction between body mass index (BMI) and
breast density in relation to breast cancer has been investi-
gated a few times [11,14-17], but only two studies investi-
gated the role of the non-dense breast tissue in relation to
breast cancer [18,19]. Stuedal et al. studied this indirectly,
by assessing whether a large area of dense tissue is more
harmful in small or large breasts, or in other words, in
combination with a small or large area of fat tissue. In a
combined population of African American and white
women, Stuedal et al. observed that the association
between percent and absolute mammographic density and
breast cancer risk was weaker in women with larger
breasts [18]. One of their explanations was that fat tissue
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any medium, provided the original work is properly cited.has a potential protective effect on breast cancer [18].
Although experimental literature provides some evidence
for this [20], most experimental studies suggested that fat
tissue secretes proteins which could stimulate proliferation
of malignant cells [21-23]. It is also known that the fat tis-
sue produces estrogens by the conversion of androgens
and increases breast cancer risk [24-27].
Stone et al. also studied which breast tissue characteris-
tics best predict breast cancer risk: dense area, non-dense
area, percent density or a combination thereof. They
observed that the dense area was a better predictor than
percent density. Further addition of non-dense area did
not alter the fit of the model, suggesting no additional role
for the fat tissue in influencing breast cancer. Unfortu-
nately, no information on breast cancer risk factors, other
than age, was available for inclusion in their models [19].
To obtain more insight into the role of the fat breast tis-
sue, we investigated the independent effects of the size of
dense tissue and the size of non-dense tissue in the breast
and their combined effects on breast cancer risk in a
nested case control study of postmenopausal Caucasian
women.
Methods
Study population
The study population comprises participants of the Pro-
spect-EPIC study [28], which is a part of the EPIC-NL
study [29]. EPIC-NL is the Dutch contribution to the Eur-
opean Prospective Investigation into Cancer and Nutrition
(EPIC) study [30,31]. The Prospect-EPIC participants were
recruited through the breast cancer screening programme
in Utrecht and vicinity. These included 17,000 women
aged between 49 and 70 years at recruitment [28]. At the
time of recruitment, anthropometric parameters were
measured and the participants filled out extensive ques-
tionnaires yielding information on demographic, lifestyle
and reproductive factors, and past and current morbidity.
Incident breast cancer cases were identified by linking
the cohort data with the regional cancer registry, IKMN
(Integraal Kankercentrum Midden Nederland), and the
national cancer registry, LKR (Landelijke Kanker Registra-
tie). Until 2007, 607 breast cancer cases had been identified
among the 17,000 breast cancer screening participants. For
each breast cancer case, the researchers used incidence
density sampling to select three controls from the cohort
[32]. In total, 1,821 controls were selected. Breast cancer
cases and controls were excluded if they previously had a
diagnosis of any type of cancer, except non-melanoma skin
cancer, or if they had less than three mammograms, which
was a prerequisite for a study on changes in mammo-
graphic density [publication in preparation]. If a person
was excluded, the respective controls were excluded too. In
total, 475 breast cancer cases and 1,187 controls were eligi-
ble for this study. As different aetiology for breast cancer in
postmenopausal women (1,217 women) compared with
premenopausal women (370 women) is likely, especially
for the role of body fat, we only selected the postmenopau-
sal women. In addition, 22 breast cancer cases and 52 con-
trols were excluded because they had breast implants or
the mammogram could not be retrieved, resulting in a
final study population of 358 cases and 859 controls.
All participants gave their informed consent and the
study was approved by The Institutional Review Board
of the University Medical Centre Utrecht.
Mammographic density assessment
Mammographic density was assessed on the left mediolat-
eral oblique mammograms (MLO) taken at the time of
recruitment into the cohort, on average six years before
diagnosis. The mammograms (all film screen) were digi-
tized with a Canon CFS300 scanner (R2 Technology,
Grand Rapids, MI, USA) with a pixel resolution of 50 μm
and 12 bits per pixel.
For assessing the mammographic density, Cumulus soft-
ware (University of Toronto, ON, Canada) was used [33].
With this software, two thresholds were set by the reader;
o n et od i s t i n g u i s ht h eb r e a s ta r e af r o mt h eb a c k g r o u n d
and a second to distinguish the dense from the non-dense
area. Furthermore, the pectoralis muscle was masked out.
The non-dense area was obtained by subtracting the dense
area from the total breast size. The size of the dense and
non-dense areas in cm
2, was determined by multiplying
the number of pixels in the respective areas by the size of
one pixel. Percent density was calculated by dividing the
dense area by the total breast area and multiplying by 100.
All mammograms were read by one single reader (ML),
blinded to participant characteristics, in batches of 53
mammograms each. Mammograms of cases and corre-
sponding controls were in the same batch but randomly
ordered. Each batch included two or three duplicate mam-
mograms to allow estimation of the within-batch intraclass
correlation coefficient. Also, a test batch was read before,
after and three times in between the batches to determine
the between-batch intraclass correlation coefficient. The
intraclass correlation coefficients for the within-batch cor-
relation as well as the between-batch correlation were
0.96, 0.96 and 1.00 for percent density, dense area and
breast area, respectively.
Statistical analysis
Patient characteristics were described within quintiles of
dense area and non-dense area among controls. For con-
tinuous variables we used means with standard deviations
if normally distributed and medians with interquartile
ranges of not normally distributed data (number of chil-
dren). For categorical variables, we show proportions. To
examine the presence of a linear trend in the distribution
of the risk factors over the dense area and non-dense
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distributed continuous data, a Jonckheere Terpstra test
for skewed continuous data (number of children) and a
chi-square linear trend test for proportions.
Correlations between density measures with BMI and
each other are calculated using the Pearson correlation
coefficient. The non-linear density measures were trans-
formed using natural logarithm in order to get normally
distributed measures.
We examined the relationship between breast measures
and breast cancer risk by calculating odds ratios and their
95% confidence intervals (95% CI) for quintiles of percent
density, dense area and non-dense area. Quintiles were
based on the distributions of controls. Multivariate logistic
regression was used to adjust for age at mammography,
age at menarche, age at first delivery (nulliparous, ≤25
years at first delivery, >25 years at first delivery), number
of children, age at menopause, hormone therapy (HT) use
(never, past, current), birth control pill use (never, past,
current), first degree relative with a history of breast can-
cer, that is, mother or sister (no/yes), height and BMI. To
investigate the independent effects of the dense and the
non-dense areas, the analyses of the dense area were addi-
tionally adjusted for the non-dense area. Despite the
strong correlation between BMI and the non-dense area,
we included the non-dense area in addition to BMI to
examine whether the local breast fat has an effect on
breast cancer risk independent of BMI. The analyses of
the non-dense area were additionally adjusted for the
dense area. The analyses are also additionally adjusted for
BMI.
In order to investigate the joint effect of dense and
non-dense tissue, these variables were dichotomized by
the median value of their distributions in the controls.
Four groups were defined, that is, women with small
areas of dense and non-dense tissue (low/low, reference
category), women with a small area of dense but a large
area of non-dense tissue (low/high), women with a large
area of dense, but a small area of non-dense tissue (high/
low) and those with a large area of both dense and non-
dense tissue (high/high). Odds ratios were adjusted for
the same confounders as described above. The relative
excess risk (RERI) of women with above median areas of
dense and non-dense tissue was calculated to assess the
level of additive interaction.
All P-values are two-sided and if below 0.05 the
results were considered statistically significant. Analyses
were conducted using PASW Statistics 17.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
At recruitment, breast cancer cases were 60 years (SD
5.4) and controls 59 years (SD 5.6) on average. The breast
cancer cases were older at the birth of their first child
than the controls (26 (SD 4.2) vs 25 (SD 4.0) years) and
also older when they became postmenopausal (48 (SD
5.6) vs 47 (SD 5.7) years). The mean age at diagnosis of
the breast cancer cases was 66 years (SD 5.8) and the
median time between the recruitment and the diagnosis
was 6 years (interquartile range: 4 to 9 years).
Distributions of breast cancer risk factors among quin-
tiles of dense tissue and non-dense tissue in controls are
presented in Table 1. Women who were older or had a
higher BMI had a smaller absolute area of dense tissue,
whereas women who were nulliparous had larger areas
of dense tissue (Table 1). Larger areas of non-dense tis-
sue were observed in women who were older or had a
higher BMI. Women had a smaller area of non-dense
tissue when they were nulliparous.
The measurements of the different breast tissues
showed that the breast cancer cases compared to the
controls (unadjusted) had a larger median area of dense
tissue (18.5 cm
2 (IQR 9.5 to 30.3) versus 14.9 cm
2 (IQR
6.9 to 29.7)) and non-dense tissue (119.3 cm
2 (IQR 87.5
to 163.5)) versus 116.4 cm
2 (IQR 84.7 to 147.5)). The
median percent density also was higher in breast cancer
cases than in controls (13.3% (6.4 to 23.4) versus 11.3%
(4.7 to 23.8)) (not in Table 1).
In Table 2 it is shown that, as expected by the way it
is calculated, a higher percent density is strongly posi-
tively correlated with a higher dense area (0.96, P <
0.001) and strongly negatively correlated with a higher
non-dense area (-0.70, P < 0.001). The dense area itself,
however, is also negatively correlated with the non-
d e n s ea r e a( - 0 . 4 7 ,P < 0.001). The non-dense area is
strongly positively correlated with BMI (0.59, P < 0.001),
and the dense area weakly negatively (-0.21, P < 0.001).
As shown in Table 3, a high percent density was asso-
ciated with higher breast cancer risk (Q5 vs Q1 OR: 1.8,
95% CI: 1.0 to 2.9, P for trend: 0.002). The risk esti-
mates for dense area seem to be somewhat stronger
than those for percent density although both risk esti-
mates are within the confidence intervals of each other
(Q5 vs Q1 OR: 2.8, 95% CI: 1.7 to 4.8, P for trend: <
0.001).
Comparing the analysis without adjusting for non-
dense area and with adjusting for non-dense area, it can
be observed that adding the non-dense breast area
somewhat increases risk estimates even after BMI has
already been included in the model, although the confi-
dence intervals partly overlap (fourth vs second ‘OR’
column of Table 3). When BMI was excluded from the
full model that also includes the non-dense area, risk
estimates remained essentially the same (third vs fourth
‘OR’ column of Table 3). When dense area, non-dense
area and BMI were all included in the same model, only
the effect estimates of the dense and non-dense tissue
area remained statistically significant.
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Page 3 of 8Table 1 Breast cancer risk factors by density measurs (quintiles* in controls (N = 859)
Absolute dense area Absolute non-dense area
Q1 Q2 Q3 Q4 Q5 Q1 Q2 Q3 Q4 Q5
(172) (172) (171) (172) (172) (172) (171) (172) (173) (171)
Mean (sd) P-trend Mean (sd) P-trend
Age at examination (years) 60.3 (5.3) 60.6 (5.5) 59.1 (5.4) 58.8 (5.7) 56.7 (5.3) <0.001 57.2 (5.1) 57.8 (5.3) 59.7 (5.4) 59.8 (5.5) 60.9 (5.6) <0.001
BMI (kg/m
2) 27.7 (4.1) 26.4 (4.0) 25.6 (3.5) 25.3 (3.7) 25.1 (3.9) <0.001 22.9 (2.4) 24.4 (2.5) 25.9 (2.8) 26.9 (3.3) 30.0 (4.4) <0.001
Height (cm) 163.4 (5.8) 163.8 (7.2) 164.1 (6.3) 164.4 (6.7) 165.0 (5.5) 0.02 164.7 (5.8) 164.3 (6.5) 163.6 (5.9) 164.0 (6.8) 164.0 (6.5) 0.20
Age at menarche(years) 13.4 (1.6) 13.5 (1.7) 13.3 (1.5) 13.5 (1.7) 13.3 (1.5) 0.72 13.6 (1.5) 13.4 (1.7) 13.4 (1.6) 13.2 (1.6) 13.3 (1.6) 0.05
Age at menopause (years) 47.1 (6.1) 47.9 (5.5) 47.1 (5.6) 48.0 (5.5) 46.9 (5.9) 0.87 47.8 (4.9) 47.4 (6.1) 47.2 (5.9) 47.1 (5.9) 47.5 (5.7) 0.45
Nr. of children
† 2.9 (1.4) 2.6 (1.6) 2.5 (1.5) 2.3 (134) 2.1 (1.4) <0.001 2.1 (1.3) 2.3 (1.5) 2.6 (1.4) 2.7 (1.6) 2.8 (1.5) <0.001
Age at first delivery (years)
‡ 25.0 (4.0) 25.4 (4.5) 24.8 (3.8) 25.2 (3.7) 24.9 (4.1) 0.87 25.4 (3.6) 24.9 (3.9) 24.7 (3.8) 25.4 (4.5) 25.0 (4.3) 0.79
N (%) N (%)
Nulliparous 9 (5.2) 16 (9.3) 20 (11.7) 23 (13.4) 33 (19.2) <0.001 32 (18.6) 23 (13.5) 17 (9.9) 16 (9.2) 13 (7.6) 0.001
HT use (ever) 32 (18.6) 40 (23.3) 39 (22.8) 56 (32.7) 50 (29.1) <0.01 50 (29.2) 48 (28.1) 41 (23.8) 39 (22.5) 39 (22.8) 0.08
Pill use (ever) 106 (61.6) 117 (68.4) 107 (62.6) 112 (65.1) 109 (63.4) 0.99 112 (65.1) 107 (62.6) 115 (66.9) 110 (63.6) 107 (62.9) 0.77
Family history of breast cancer 28 (16.7) 20 (12.0) 27 (16.0) 23 (14.0) 26 (15.6) 0.99 29 (17.4) 25 (14.8) 21 (12.4) 20 (12.0) 29 (17.7) 0.80
* Quintiles by controls only
‡ Parous women only
† The median nr. of children is shown in this table
Bold p-trends are statistically significant
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8After adjustment for dense area, a large non-dense area
was also related with a higher breast cancer risk (Q5 vs
Q1 OR: 2.4 95% CI 1.3 to 4.2, P for trend: < 0.001).
Again, exclusion of BMI did not further change the risk
estimates (third vs fourth ‘OR’ column of Table 3).
Since BMI and non-dense area are closely related (cor-
relation coefficient: 0.59) multicollinearity may have
affected these models. To circumvent this problem we
repeated analyses, including BMI and the residuals of
non-dense area regressed on BMI. This did, however, not
lead to different results.
Women with a large (above median, that is, >14.9 cm
2)
area of dense tissue and a small (below median, that is,
<116.4 cm
2) area of non-dense tissue showed a slightly
higher breast cancer risk than with a small area of both
tissue types (OR 1.6, 95% CI 1.0 to 2.5). The highest risk
was observed in women with large areas of both dense
and non-dense tissue (OR 1.8, 95% CI 1.1 to 3.0). This
risk for women with high dense and non-dense area
combined was slightly higher than the sum of the risk for
women with large areas of either one of the high risk tis-
sues, but not statistically significantly (RERI 0.24, 95% CI:
Table 3 Breast tissue measures and breast cancer risk
Quintiles N (Case/Controle) Median (%)
(IQR)
OR (95% CI)* OR (95% CI)** OR
(95% CI)***
OR (95% CI)****
Percent Density
1 53/171 2.2 (1.5 to 3.0) Ref Ref
2 61/171 5.8 (4.8 to 7.0) 1.4 (0.9 to 2.3) 1.6 (1.0 to 2.5)
3 88/172 11.4 (10.0 to 13.4) 1.8 (1.1 to 3.3) 2.1 (1.3 to 3.3)
4 88/173 20.3 (18.1 to 23.5) 2.1 (1.6 to 3.4) 2.5 (1.6 to 4.1)
5 68/172 38.9 (38.9 to 48.9) 1.4 (1.0 to 2.9) 1.8 (1.0 to 2.9)
P-trend 0.029 0.002
Dense Area
† Median (cm
2)
(IQR)
1 46/172 3.6 (2.3 to 4.6) Ref Ref Ref Ref
2 55/172 8.3 (6.9 to 9.5) 1.3 (0.8 to 2.1) 1.4 (0.9 to 2.4) 1.5 (0.9 to 2.4) 1.5 (0.9 to 2.4)
3 86/171 14.9 (12.6 to 16.8) 2.1 (1.3 to 3.3) 2.3 (1.4 to 3.7) 2.6 (1.6 to 4.2) 2.6 (1.6 to 4.2)
4 93/172 25.5 (22.6 to 29.3) 2.4 (1.5 to 3.8) 2.6 (1.7 to 4.2) 3.2 (2.0 to 5.3) 3.2 (2.0 to 5.3)
5 78/172 44.4 (39.5 to 54.4) 1.9 (1.1 to 3.0) 2.1 (1.3 to 3.4) 2.9 (1.7 to 4.9) 2.8 (1.7 to 4.8)
P-trend 0.001 <0.001 <0.001 <0.001
Non Dense Area
‡ Median (cm
2)
(IQR)
1 65/172 61.0 (48.2 to 69.9) Ref Ref Ref Ref
2 61/171 90.5 (84.2 to 96.5) 1.0 (0.6 to 1.5) 0.9 (0.6 to 1.5) 1.1(0.7 to 1.8) 1.1 (0.7 to 1.8)
3 72/172 115.5 (109.4 to 121.3) 1.2 (0.8 to 1.9) 1.2 (0.7 to 1.8) 1.6 (1.0 to 2.5) 1.5 (0.9 to 2.4)
4 65/173 141.7 (133.2 to 148.9) 1.0 (0.6 to 1.6) 0.9 (0.6 to 1.5) 1.4 (0.9 to 2.3) 1.4 (0.8 to 2.3)
5 95/171 186.7 (172.1 to 211.8) 1.7 (1.1 to 2.5) 1.4 (0.9 to 2.4) 2.6 (1.6 to 4.2) 2.4 (1.3 to 4.2)
P-trend 0.009 0.115 <0.001 <0.001
* Potential confounders
** Potential confounders and BMI
*** Potential confounders and Breast Tissue (
† Adjusted for Non-Dense Area,
‡ Adjusted for Dense Area)
**** Potential confounders, BMI and Breast Tissue (
† Adjusted for Non-Dense Area,
‡ Adjusted for Dense Area)
Potential confounders: Age at mammography, Height, Age at Menarche, Age First Delivery (Nulliparous, ≤25 years at first delivery, >25 years at first delivery), Nr.
of children, Age Menopause (Premenopausal, ≤50 years at menopause, >50 years at menopause), HT use (Never, Current, Ever), Pill use (Never, Current, Ever),
Family History (No/Yes).
Table 2 Pearson Correlations of density measures with each other and with BMI*
Breast area Dense area Non-dense area Percent density BMI
Breast area 1 -0.18 0.90 -0.46 0.62
Dense area 1 -0.47 0.96 -0.21
Non-dense area 1 -0.70 0.59
Percent density 1 -0.37
BMI 1
*The p-values of all correlations are statistically significant (< 0.001)
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necessarily have a higher breast cancer risk, as can be
observed from the median breast sizes for the risk cate-
gories in Table 4. Women within the ‘high dense - low
non-dense’ category have a significantly increased risk,
whereas women in the ‘low dense - high non - dense’
category do not show an increased risk, despite both
categories have larger breasts.
Discussion
In this paper, we investigated the role of dense and fatty
breast tissue in relation to breast cancer risk. We found
that not only a large area of fibroglandular tissue is asso-
ciated with a higher breast cancer risk, but also that a large
area of fat breast tissue, even after taking BMI into account,
has an independent effect on breast cancer risk. Women
who have both a large area of fibroglandular tissue and a
large area of fat tissue seem to have the highest breast can-
cer risk. It should be noted that the relationship with breast
cancer is stronger for the dense than for the non-dense
area. Therefore, the resulting risk depends on the composi-
tion of the breast and not simply on the size of the breast.
When studying dense breast tissue in relation to breast
cancer risk, adjustment for non-dense tissue seems to
change risk estimates to a larger extent than adjustment
for BMI. This indicates that adjustment for non-dense tis-
sue should be considered when studying associations
between dense area and breast cancer risk.
The harmful effect of a large area of dense tissue on
breast cancer risk is established, and could be explained by
the fact that proliferating cells are the actual target tissue
for breast cancer development [3,34]. Also, it has often
been hypothesized that the area of the dense tissue would
reflect the effect of estrogens on the breast, because many
determinants of mammographic density are related to hor-
mones (parity, menopause, hormone therapy) [34]. As
many articles in primarily postmenopausal women,
however, show no association between estrogen levels and
breast density [34,35], it seems likely that local estrogen
production in the breast rather than circulating estrogen
levels are related to dense tissue. This also fits with the
finding of Tamimi et al. who showed that high circulating
estrogen levels and high breast density increase breast can-
cer risk independently from one another [36]. Evidence for
local estrogen production being responsible for high breast
density was found by Vachon et al. [37], who showed
higher aromatase activity in dense than in non-dense tis-
sue. An independent harmful effect of fatty breast tissue
has not been described before, but could be explained by
the fact that the fat tissue is an important source of local
estrogens in the breast [24-27].
A large area of fatty breast tissue could also increase
breast cancer risk through adipocytokines, such as leptin
and adiponectin, which are secreted by the fat tissue. Lep-
tin promotes breast cancer cell growth, whereas adiponec-
tin reduces cell proliferation and enhances apoptosis. A
higher body mass index is associated with increased secre-
tion of leptin and decreased secretion of adiponectin [38].
The balance between leptin and adiponectin might also be
an important factor in the development of breast cancer
as described in the review by Grossmann et al. [39].
Currently, two studies have investigated the role of the
breast fat tissue with different results. Stone et al. investi-
gated the role of the non-dense area in a group of women
in the United Kingdom comparable to our study popula-
tion. Although the highest quintile of non-dense area gave
a somewhat higher odds ratio than the other quintiles, they
did not find a significant association between non-dense
area and breast cancer risk. Stone et al. concluded that the
model with the dense area alone was the most parsimo-
nious model [19]. In this study, the results could only be
adjusted for age and dense area and not for other breast
cancer risk factors. When we only adjusted for age and
dense area like Stone did, we observed a weaker effect than
Table 4 Combined effect of dense and fat tissue on breast cancer risk
N Case/
Control
Dense area
(min.–max.)
Non-dense area
(min.–max.)
(IQR)
Median
breast size
Median
percent density
OR*; 95% CI OR**; 95% CI
Low Dense
† - Low
Non-Dense
‡
41/138 0.8 to 14.9 cm
2 38.3 to 116.3 cm
2 102.9 cm
2 9.34% Ref. Ref.
Low Dense - High
Non-Dense
102/291 0.3 to 14.7 cm
2 116.4 to 289.6 cm
2 164.6 cm
2 3.54% 1.18; 0.78 to 1.85 1.02; 0.64 to 1.63
High Dense - Low
Non-Dense
129/289 15.1 to 98.2 cm
2 12.5 to 116.1 cm
2 115.3 cm
2 28.24% 1.58; 1.02 to 2.44 1.58; 1.02 to 2.45
High Dense - High
Non-Dense
86/139 14.9 to 99.2 cm
2 116.6 to 258.6 cm
2 175.1 cm
2 13.69% 2.15; 1.34 to 3.45 1.84; 1.12 to 3.02
RERI 0.39; - 0.43 to 1.20 0.24; -0.52 to 1.00
* Adjusted for age at examination, height, age at menarche, age at first delivery (nulliparous, ≤25 years at first delivery, >25 at first delivery), number of children,
age at menopause (premenopausal, ≤50 years at menopause, >50 years at menopause), HT use (never, current, ever), pill use (never, current, ever), family history
of breast cancer (yes/no)
** Same as *, but additionally adjusted for BMI
† Dense area was split by the median which was 14.9 cm
2
‡ Non-dense area was split by the median which was 116.4 cm
2
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Page 6 of 8in our fully adjusted models; however, it is still statistically
significant (OR 1.8, 95% CI 1.1 to 2.7 vs. 2.4, 95% CI 1.3 to
4.2). Therefore, this cannot entirely explain the discrepant
results.
Stuedal et al. studied the role of the non-dense tissue
indirectly by investigating the effect of the breast size on
the relationship between mammographic density and
breast cancer risk. They found that the association
between breast density and breast cancer risk was
weaker in women with larger breasts. This could indi-
cate that the fat tissue is protective against breast cancer
[18]. This discrepancy between their study and ours
could potentially be explained by differences in study
populations. In our study, the mean age of the women
was 59 years old and only postmenopausal women were
included. The study population of Stuedal and collea-
gues was considerably younger, namely 49 years old on
average and most women were still premenopausal. In
postmenopausal women, estrogens are mainly synthe-
sized in the fat tissue, through conversion of androgens,
whereas in premenopausal women, estrogens are mainly
synthesized in the ovary [38]. This may explain why in
our postmenopausal population a large area of fat tissue
in the breast is related to higher breast cancer risk,
while this was not observed in the study of Stuedal et al.
According to Stuedal et al., their findings might also be
explained by a higher proportion of dense tissue in larger
breasts having a more ‘supportive’ role than it does in
smaller breasts and, therefore, it may be less correlated
with the number of epithelial cells at risk and, hence, it is
more weakly associated with breast cancer risk [18]. If
true, this too may be different for pre- and postmenopau-
sal women. It has been suggested before that high density
in postmenopausal women may represent something dif-
ferent from high density in premenopausal women [34].
The group of premenopausal women in our study was too
small to perform a separatea n a l y s i su p o nt of u r t h e r
explore this explanation.
A strength of our case-control study is that it is nested
in a large cohort study, in which mammograms and
questionnaire information were collected long before
breast cancer developed, reducing the chance of recall
bias. The questionnaires contained extensive information
about the potential breast cancer risk factors, allowing
extensive confounder adjustment. Also, due to the long
follow-up time, we were able to study breast density well
before diagnosis, making it unlikely that density is influ-
enced by the presence of a tumor, or that our findings
are influenced by so-called masking bias [40]. A weakness
of our older study population is the limited number of
women with a very high percent density. This is inherent
to the Dutch screening programme, which is restricted to
women between the ages of 50 and 75 years old. Another
limitation is that for this study we only have film-screen
mammograms at our disposal. This has the inherent dis-
advantage that technical characteristics and breast thick-
ness are not taken into account which could give less
precise estimates for the dense and non-dense tissue [41].
Full field digital mammography, which has been routinely
used in the Dutch screening programme for a few years,
is likely to provide a more precise estimate of dense and
non-dense tissue volume in the coming years.
Conclusions
We observed that besides the size of dense tissue, the size
of non-dense tissue also plays a role in the development of
breast cancer. When studying dense breast tissue in rela-
tion to breast cancer risk, adjustment for non-dense tissue
m a yg i v em o r ev a l i dr e s u l t st h a na d j u s t m e n tf o rB M I .
Although not statistically significant, the results also give
some indication that a large area of fibroglandular tissue
could be related to higher breast cancer risk when sur-
rounded by a large, compared to a small area of fat tissue.
Further research is warranted to confirm this effect.
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